Insulin resistance in non-diabetic patients with chronic hepatitis C: What does it mean?;Resistência insulínica em portadores de hepatite crônica C não diabéticos: Qual o significado?

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 55, Issue 6, 2011, Pages 412-418

  de Souza, Aécio Flávio Meirelles ^a   de Lima Pace, Fábio Heleno ^a   Chebli, Júlio Maria Fonseca ^a   de Castro Ferreira, Lincoln Eduardo Villela Vieira ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Chronic hepatitis C; HOMA IR; Insulin resistance; Liver fibrosis

Indexed keywords

BIOLOGICAL MARKER;

ANTHROPOMETRY; ARTICLE; BLOOD; BRAZIL; DIABETES MELLITUS; EPIDEMIOLOGY; FEMALE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REFERENCE VALUE;

ANTHROPOMETRY; BIOLOGICAL MARKERS; BRAZIL; DIABETES MELLITUS; EPIDEMIOLOGIC METHODS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 80054732368     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302011000600008     Document Type: Article

References (41)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterolol. 2007;13(17):2436-41.
2. Fonseca J. Epidemiologia da infecção pelo vírus da hepatite C no Brasil. Relatório do Grupo de Estudo da Sociedade Brasileira de Hepatologia. GED. Gastroenterologia Endoscopia Digestiva. 1999;18(suppl 1):S3-S8.
3. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama. 2000;284(4):450-6.
4. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C-natural history and cofactors. Aliment Pharmacol Ther. 2005;22(Suppl. 2):74-8.
5. John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010;53(2):245-51.
6. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730-9.
7. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054-8.
8. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125:1695-704.
9. Sanyal AJ. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int. 2011;31S1:23-8.
10. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54:1003-08.
11. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diab Med. 2006;23:469-80.
12. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24(5):695-08.
13. Setsi G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab. 2006;20(4):665-79.
14. LeRoith D. Beta cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med. 2002;113 (6A):3s-11s.
15. Romero Gómez M, Fernández-Rodríguez CM, Andrade RJ, Diago M, Alonso S, Planas R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48:721-7.
16. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006;29:2462-6.
17. López RA, Romero-Gómez M. La resistencia a la insulina en la hepatitis crónica C. GH continuada. 2010; 9(2):73-6.
18. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Virahep-C Study Group. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80-7.
19. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712-8.
20. Chu CJ, Lee SD, Hung TH, Lin HC, Hwang SJ, Lee FY, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther. 2009;29:46-54.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93.
22. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21(1):3-16.
23. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16):1640-5.
24. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care. 1996;19:998-1000.
25. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328-33.
26. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166:196-03.
27. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592-9.
28. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care.1999;22:818-22.
29. Bonora E, Targher G, Alberiche M, Bonadonna R, Saggiani F, Zenere M, Monauni T, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
30. Grasso A, Malfatti F, Leo P, Martines H, Fabris P, Toscanini F, et al. Insulin resistance predicts rapid virological response in non--diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol. 2009;51:984-90.
31. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault M-P, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416-23.
32. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-41.
33. Duseja A, Dhiman RK, Chawla Y, Thumburu KK, Kumar A, Das A, et al. Insulin resistance is common in patients with predominantly genotype 3 chronic hepatitis C. Dig Dis Sci. 2009;54:1778-82.
34. Hsu C-S, Liu C-J, Liu C-H, Wang C-C, Chen C-L, Lai M-Y, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int. 2008;28:271-77.
35. Geloneze B, Pereira JA, Pareja JC, Lima MM, Lazarin MA, Souza IC et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS): Arq Bras Endocrinol Metabol. 2009;53(2):293-300.
36. Armoni M, Harel C, Karnieli E. Transcriptional regulation of the GLUT4 gene: from PPAR-gamma and FOXO1 to FFA and inflammation. Trends Endocrinol Metab. 2007;18(3):100-7.
37. Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci. 2005;330(6):280-9.
38. Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP. Body distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension. 2005;46(5):1186-93.
39. Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15:1537-47.
40. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: what does it really matter? Gut. 2006;55:123-30.
41. Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci. 2010;55:560-78.